Boris Freidlin

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Finite Element Analysis

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

Clinical trials (London, England)

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Boris Freidlin, Edward L Korn
Two-to-One Randomization: Rarely Advisable. JCO oncology practice (2024)
Boris Freidlin, Edward L Korn
Efficiency of Biomarker-Driven Clinical Trial Designs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Megan K D Othus, Boris Freidlin, Edward L Korn
Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Boris Freidlin, Edward L Korn
Efficiency of Biomarker-Driven Clinical Trial Designs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (12) (2024)
Boris Freidlin, Edward L Korn
Efficiency of Biomarker-Driven Clinical Trial Designs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (12) (2024)
Boris Freidlin, Edward L Korn
Efficiency of Biomarker-Driven Clinical Trial Designs. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (12) (2024)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, Geoffrey I Shapiro, Lisa Meier McShane, Boris Freidlin, Roisin E O'Cearbhaill, Suzanne George, Julia L Glade Bender, Gary H Lyman, James V Tricoli, David R Patton, Stanley R Hamilton, Robert C Gray, Douglas S Hawkins, Bhanumati Ramineni, Keith T Flaherty, Petros D Grivas, Timothy Anthony Yap, Jordan D Berlin, James H Doroshow, Lyndsay N Harris, Jeffrey A Moscow
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, Geoffrey I Shapiro, Lisa Meier McShane, Boris Freidlin, Roisin E O'Cearbhaill, Suzanne George, Julia L Glade Bender, Gary H Lyman, James V Tricoli, David R Patton, Stanley R Hamilton, Robert C Gray, Douglas S Hawkins, Bhanumati Ramineni, Keith T Flaherty, Petros D Grivas, Timothy Anthony Yap, Jordan D Berlin, James H Doroshow, Lyndsay N Harris, Jeffrey A Moscow
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Boris Freidlin, Larissa A Korde, Edward L Korn
Timing and Reporting of Secondary Overall Survival End Points for Phase III Trials in Advanced/Metastatic Disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Yixuan Zhao, Ying Yuan, Edward L Korn, Boris Freidlin
Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Edward L Korn, Boris Freidlin
Time trends with response-adaptive randomization: The inevitability of inefficiency. Clinical trials (London, England) 19 (2) (2022)
Edward L Korn, Carmen J Allegra, Boris Freidlin
Clinical Benefit Scales and Trial Design: Some Statistical Issues. Journal of the National Cancer Institute 114 (9) (2022)
Boris Freidlin, Chen Hu, Edward L Korn
Are restricted mean survival time methods especially useful for noninferiority trials? Clinical trials (London, England) 18 (2) (2021)
Boris Freidlin, Chen Hu, Edward L Korn
Reply to Quartagno et al. Clinical trials (London, England) 18 (6) (2021)